News &
Events
CORPORATE ANNOUNCEMENTS & PORTFOLIO UPDATES
Featured Article
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration on for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5% in 15 g and 30 g tubes, a generic version of reference listed drug ZOVIRAX (acyclovir) Ointment 5%. For more updates, please feel free to email us info@solaris-pharma.com
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil)
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil)Solaris Pharma Corporation located Bridgewater, New Jersey
Solaris Pharma Announces Launch of Clindamycin Phosphate Gel USP, 1% in 30 g and 60 g Tubes
Solaris Pharma Corporation located in Bridgewater, New Jersey is pleased to announce the launch of Clindamycin Phosphate Gel USP,
Solaris Pharma Receives FDA Approval for Clindamycin Phosphate Gel USP, 1% (Twice-A-Day)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for
Solaris Pharma Receives FDA Approval for Acyclovir Ointment USP, 5%
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration on for
Solaris Pharma Receives FDA Approval for Clobetasol Propionate Cream USP, 0.05%
Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its